Medistep Healthcare IPO opens today. Check GMP, issue size, price band and other details

Synopsis

Medistep Healthcare, an Ahmedabad-based pharmaceutical and wellness company, is launching its Rs 16.10 crore IPO on August 8 via the NSE SME platform. The IPO, priced at Rs 43 per share, has seen strong investor interest, with grey market premium surging to 40%.

Ahmedabad-based Medistep Healthcare is set to open its Rs 16.10 crore IPO for subscription on August 8, marking its entry into the capital markets via the NSE SME platform. The public issue, priced at a fixed rate of Rs 43 per share, will close on August 12, with allotment expected the following day. Shares are scheduled to list on August 18, 2025.

Despite its modest size, the issue has drawn notable market interest. The grey market premium (GMP) has surged to 40% over the issue price ahead of the listing, signalling strong investor appetite and potential for upside on debut. At a GMP of Rs 17, the implied listing price is around Rs 60 per share.

The IPO comprises a 100% fresh issue of 37.44 lakh equity shares, with no offer for sale component. Out of the total issue.

The issue is being led by Fast Track Finsec as the book-running lead manager, while Cameo Corporate Services is the registrar.

Medistep Healthcare is a pharmaceutical and wellness products company. It manufactures and trades a range of items including sanitary pads (DryStep brand), energy powder (VitaStep Z), nutraceuticals, pharmaceuticals, and intimate and surgical products.

The company claims to focus on affordable, quality-driven offerings tailored to essential healthcare and hygiene needs, and it plans to scale both manufacturing and trading verticals post-listing.

The company posted revenues of Rs 49.66 crore in FY25, a 27% YoY increase, with PAT at Rs 4.14 crore, up 25%.

The company intends to use IPO proceeds to fund plant and machinery purchases, meet working capital needs (Rs 12.34 crore), and for general corporate purposes.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)

...moreless

...moreless